艾曲泊帕治疗难治/复发性钻石-布莱克范贫血
这项单中心、单臂先导研究(NCT04269889)评估了每日固定剂量艾曲泊帕治疗15例输血依赖(每3-5周输血)的钻石-布莱克范贫血(DBA)患者6个月的安全性和红系反应,中位年龄18岁(范围2-56)。1例有应答者血红蛋白持续改善且红细胞输血频率降低>50%,但7/15(41%)患者因无症状性血小板增多症需要减量或持续停药。尽管应答率低,艾曲泊帕已在数例DBA患者中改善红系生成且安全性良好;因血小板增多症导致的剂量限制可能造成铁螯合不足,从而无法减少血红素生成和改善大多数患者的贫血。
要点
- 15例输血依赖DBA患者接受每日固定剂量艾曲泊帕6个月,1例有应答者血红蛋白持续改善且红细胞输血频率降低>50%。
- 7/15(41%)患者因无症状性血小板增多症需要减量或持续停药。
- 作者认为因血小板增多症导致的剂量限制可能造成铁螯合不足,从而无法减少血红素生成和改善大多数患者的贫血。
核心结论
- 尽管应答率低,艾曲泊帕已在数例DBA患者中改善红系生成且安全性良好。
- 因血小板增多症导致的剂量限制可能造成铁螯合不足,从而无法减少血红素生成和改善大多数患者的贫血。
- 未来工作将聚焦于患者红系生成动力学以及使用不影响其他造血谱系的血红素合成抑制剂。
研究设计与样本
- 单中心、单臂先导研究(NCT04269889),评估每日固定剂量艾曲泊帕治疗6个月的安全性和红系反应。
- 共治疗15例输血依赖(每3-5周输血)的DBA患者,中位年龄18岁(范围2-56)。
主要发现
- 1例有应答者血红蛋白持续改善且红细胞输血频率降低>50%。
- 7/15(41%)患者因无症状性血小板增多症需要减量或持续停用艾曲泊帕。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diamond-Blackfan anaemia (DBA) is a rare, inherited bone marrow failure syndrome with a ribosomal defect causing slowed globin chain production with normal haem synthesis, causing an overabundance of reactive iron/haem and erythroid-specific cellular toxicity. Eltrombopag, a non-peptide thrombopoietin receptor agonist, is a potent intracellular iron chelator and induced a robust durable response in an RPS19-mutated DBA patient on another trial. We hypothesized eltrombopag would improve RBC production in DBA patients. We conducted a single-centre, single-arm pilot study (NCT04269889) assessing safety and erythroid response of 6 months of daily, fixed-dose eltrombopag for DBA patients. Fifteen transfusion-dependent (every 3-5 weeks) patients (median age 18 [range 2-56]) were treated. One responder had sustained haemoglobin improvement and >50% reduction in RBC transfusion frequency. Of note, 7/15 (41%) patients required dose reductions or sustained discontinuation of eltrombopag due to asymptomatic thrombocytosis. Despite the low response rate, eltrombopag has now improved erythropoiesis in several patients with DBA with a favourable safety profile. Dosing restrictions due to thrombocytosis may cause insufficient iron chelation to decrease haem production and improve anaemia in most patients. Future work will focus on erythropoiesis dynamics in patients and use of haem synthesis inhibitors without an impact on other haematopoietic lineages.
引用
- Duncan BB, Lotter JL, Superata J, et al. Treatment of refractory/relapsed Diamond-Blackfan anaemia with eltrombopag. Br J Haematol. 2024. PMID: 38462764. doi:10.1111/bjh.19357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。